申请人:SmithKline Corporation
公开号:US04192872A1
公开(公告)日:1980-03-11
6-Halo-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines whose structures have a lower alkyl substituted at the 3 or N-position have potent and often specific anti-Parkinsonism activity by means of their central dopaminergic effect. The lead compound of the series is 6-chloro-3-methyl-1-phenyl-7,8-dihydroxy-2,3,4,5-tetrahydro-1H-3-benzazepi ne as the base or its salts such as the hydrochloride, hydrobromide or methane sulfonate.
结构中在3位或N位有低碳烷基取代的6-卤代-7,8-二羟基-1-苯基-2,3,4,5-四氢-1H-3-苯并吖啶类化合物具有强效且通常具有特异的抗帕金森病活性,通过其中枢多巴胺效应实现。该系列的首选化合物是6-氯-3-甲基-1-苯基-7,8-二羟基-2,3,4,5-四氢-1H-3-苯并吖啶或其盐,如盐酸盐、溴化物或甲磺酸盐。